Melanoma-associated antigen A1 (MAGE-A1), Melanoma-associated antigen A2 (MAGE-A2), Melanoma-associated antigen A3 (MAGE-A3), Melanoma-associated antigen A6 (MAGE-A6) (MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A6)

The melanoma-associated antigen A (MAGE-A) family, which includes MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A6, are cancer/testis antigens characterized by restricted expression in normal adult tissues (primarily testis) and aberrant expression in a wide range of tumor types[2][3]. They function as regulators of cell cycle, apoptosis, and cellular metabolism, and facilitate tumor cell immune evasion. MAGE-A3 and MAGE-A6, in particular, form complexes with the E3 ubiquitin ligase TRIM28 to target the tumor suppressor AMPK for degradation, promoting tumorigenesis[1][2]. MAGE-A antigens are studied as targets for cancer immunotherapy, including vaccines, though clinical results have been disappointingly limited in efficacy, highlighting the complexity of their biology and regulatory role in cancer[3][2].

Other names

Cancer/testis antigen family 1MAGE-1MAGE-2MAGE-3CT7 (for MAGE-A1)CT10 (for MAGE-A4, contextually related in the literature as some cross-labeling occurs)Melanoma antigen gene

For immunotherapies and vaccines: Elicit anti-tumor T cell immune responses by presenting MAGE-A-derived peptides on tumor cells[3] For drugs affecting downstream pathways: Counteract MAGE-A–mediated suppression of AMPK, enhancing tumor cell sensitivity to metabolic stress[2]